Ionis Pharmaceuticals

Ionis Pharmaceuticals Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

Ionis Pharmaceuticals key operating metrics including Phase II Trials Products, environmental, and social and governance score (ESG).

Phase II Trials Products

7.1%

FY, 2023

Phase III Trials Products

28.6%

FY, 2023

Products Marketed

66.7%

FY, 2023

Operating Metrics

Metrics	FY, 2021	FY, 2022	FY, 2023
Phase II Trials Products	22	14	13
Phase III Trials Products	6	7	9
Products Marketed	3	3	5
Phase I Trials Products			1
Trademarks (Europe)			5
Trademarks (US)			6

50-59 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub